13515-76-9

Usage

Uses

Used in Organic Synthesis:
N-(TRIPHENYLMETHYL)-DL-SERINE METHYL ESTER is used as a protecting group for the hydroxyl group of serine, ensuring the stability and reactivity of serine during complex organic synthesis processes.
Used in Pharmaceutical Research:
N-(TRIPHENYLMETHYL)-DL-SERINE METHYL ESTER is used as a reagent in the synthesis of pharmaceuticals, playing a vital role in the protection of the reactive hydroxyl group, which is crucial for the successful synthesis of target molecules.
Used in the Creation of Novel Molecules:
N-(TRIPHENYLMETHYL)-DL-SERINE METHYL ESTER is used as a building block for the development of new molecules with potential biological activity, contributing to the discovery of innovative compounds in the field of pharmaceuticals and biochemistry.
Used in Chemical Research:
N-(TRIPHENYLMETHYL)-DL-SERINE METHYL ESTER is utilized in chemical research to explore its properties and potential applications, further expanding the understanding of its role in organic chemistry and its implications in the synthesis of complex molecules.

InChI:InChI=1/C23H23NO3/c1-27-22(26)21(17-25)24-23(18-11-5-2-6-12-18,19-13-7-3-8-14-19)20-15-9-4-10-16-20/h2-16,21,24-25H,17H2,1H3

Upstream product

• 5680-80-8 methyl (2S)-2-amino-3-hydroxypropanoate hydrochloride 
• 76-83-5 trityl chloride 
• 2788-84-3 (S)-serine methyl ester 
• 141-78-6 ethyl acetate 
• 2104-89-4 Ser-OMe 
• 5619-04-5 methyl 2-amino-3-hydroxypropanoate hydrochloride 
• 78646-25-0 4-dimethylamino-1-N-(triphenylmethyl)pyridinium chloride 

Downstream Products

• 126271-42-9 O-octadecylcarbamoyl-N-tritylserine methyl ester 
• 76357-18-1 methyl 1-tritylaziridine-2-carboxylate 
• 1449601-09-5 DL-O-(1,3-dihydro-2,5-dioxo-1-pyrolidinyl)-N-(triphenylmethyl)methyl ester 
• 4465-45-6 (S)-3-hydroxy-2-(tritylamino)propanoic acid 
• 257887-94-8 1-O-(5'-carbomethoxypentyl)-2-tetrahydropyranyl-sn-glyceryl 2,2,2-trichloro-tert-butyl 2-carbomethoxy-2-(N-triphenylmethylamino)ethyl phosphite 
• 119147-46-5 O-<4,6-Bis(octadecyloxy)-1,3,5-triazin-2-yl>-N-trityl-L-serin-methylester 
• 119147-45-4 O-<4,6-Bis(dodecyloxy)-1,3,5-triazin-2-yl>-N-trityl-L-serin-methylester 
• 76357-12-5 (S)-methyl3-((methylsulfonyl)oxy)-2-(tritylamino)propanoate 
• 161009-63-8 (S)-3-[5-(2-Methoxy-ethoxymethoxy)-2-nitro-benzyloxy]-2-(trityl-amino)-propionic acid methyl ester 
• 161009-62-7 (S)-3-[2-(2-Methoxy-ethoxymethoxy)-5-nitro-benzyloxy]-2-(trityl-amino)-propionic acid methyl ester 
• 75154-68-6 methyl (2S)-N-tritylaziridine-2-carboxylate 
• 88109-07-3 tris(N-trityl-L-serine) trilactone 

Relevant academic research and scientific papers

Synthesis of novel benzoxaborole-containing phenylalanine analogues

The synthesis of novel benzoxaborole-containing phenylalanine analogues 2 and 3 has been developed. The key steps involve the preparation of appropriate precursors from the readily available amino acids and the formation of benzoxaborole ring directly in

Fluorinated O-phenylserine residues enhance the broad-spectrum antimicrobial activity of ultrashort cationic lipopeptides

As a crucial structural element in many antimicrobial lipopeptides, phenylalanine poses a potential, but sensitive, point of modification in the pursuit of enhancing the antimicrobial efficacy of peptide antibiotics. We report the synthesis and applicatio

BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS

The invention relates to 1,5-benzothiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also r

MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS

The compounds of the present invention are represented by the following compounds having Formula I and Formula (I'): where the substituents R1, R2, R2', R3, R4, R5, R', R", X, Y, and Z are as defined herein and where the substituents R1, R2, R3, R4, R5, R', R", X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Preparation method of 2,3-diamido methyl propionate

The invention provides a preparation method of 2,3-diamido methyl propionate. According to the method, serine is used as a raw material, in methyl alcohol, thionyl chloride is used as a catalyst for preparing serine methylester, then the serine methyleste

Highly Chemoselective Deprotection of the 2,2,2-Trichloroethoxycarbonyl (Troc) Protecting Group

Nonreducing, pH-neutral conditions for the selective cleavage of the 2,2,2-trichloroethoxycarbonyl (Troc) protecting group are reported. Using trimethyltin hydroxide in 1,2-dichloroethane, Troc-protected alcohols, thiols, and amines can be selectively unmasked in the presence of various functionalities that are incompatible with the reducing conditions traditionally used to remove the Troc group. This mild deprotection protocol tolerates a variety of other hydrolytically sensitive and acid/base-sensitive moieties as well.

Activation of Remote meta-C?H Bonds in Arenes with Tethered Alcohols: A Salicylonitrile Template

Palladium-catalyzed activation of remote meta-C?H bonds in arenes containing tethered alcohols was achieved with high regioselectivity by using a nitrile template. Computational studies on the macrocyclic transition state of the regioselectivity-determini

PHOSPHONATE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I''' or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit

Copper(I)-Mediated Denitrogenative Macrocyclization for the Synthesis of Cyclic α3β-Tetrapeptide Analogues

A copper(I)-mediated denitrogenative reaction has been successfully developed for the preparation of cyclic tetrapeptides. The key reactive intermediate, ketenimine, triggers intramolecular cyclization through attack of the terminal amine group to generate an internal β-amino acid with an amidine linkage. The chemistry developed herein provides a new synthetic route for the preparation of cyclic α3β-tetrapeptide analogues that contain important biological properties and results in rich structural information being obtained for conformational studies. With the success of this copper(I)-catalyzed macrocyclization, two histone deacetylase inhibitor analogues consisting of the cyclic α3β-tetrapeptide framework have been successfully synthesized.

NOVEL COMPOUNDS

A compound of formula (I) or a pharmaceutically acceptable derivative thereof, (formula 1) wherein R1,R2, R3, R4, R5, X, m and n are defined in the specification; a process for preparing such compounds; a pharmaceutical composition comprising such compounds; and the use of such compounds in medicine.